截至11月12日收盘，细胞免疫治疗概念上涨2.20%，位居概念板块涨幅第1，板块内，43股上涨，开能 健康20%涨停，南京新百、济民健康、中源协和等涨停，三元基因、冠昊生物、诚达药业等涨幅居前， 分别上涨12.45%、7.47%、6.34%。跌幅居前的有博腾股份、海特生物、睿智医药等，分别下跌1.33%、 1.22%、1.00%。 | 300199 | 翰宇药 | 0.35 | 4.34 | -1121.74 | -1.71 | | --- | --- | --- | --- | --- | --- | | | 业 | | | | | | 300009 | 安科生 物 | -0.36 | 4.44 | -1123.10 | -1.84 | | 300358 | 楚天科 | 0.56 | 4.76 | -1128.92 | -3.79 | | | 技 | | | | | | 300006 | 莱美药 | 0.19 | 5.43 | -1328.44 | -4.41 | | | 业 | | | | | | 30051 1 | 雪榕生 | -0.26 | 5.70 | -1400.49 | -5.79 | | | ...

Market Overview - The A-share market experienced a slight decline, with the Shanghai Composite Index down by 0.07% and the Shenzhen Component Index down by 0.36% [3][4] - The total trading volume in the two markets was 1.95 trillion, a decrease of 486 billion compared to the previous trading day [6] Sector Performance - Defensive sectors showed strength, particularly the oil and gas sector, with companies like Shihua Oil and Zhun Oil both hitting the daily limit [1] - The pharmaceutical sector continued to rise, led by cell immunotherapy concepts, with stocks like Kaineng Health and Jimin Health reaching the daily limit [1] - The banking sector performed strongly, with Agricultural Bank of China and Industrial and Commercial Bank of China both reaching historical highs [1] - The consumer sector was active in parts, with companies like Sanyuan and Zhongrui achieving three consecutive limits, and Dongbai Group hitting four limits in six days [1] - The lithium battery sector saw a late rally, with Tianji shares achieving three limits in four days [1] - In contrast, the superhard materials sector experienced significant declines, with World falling over 10% [1][2] Market Statistics - A total of 3,563 stocks declined, while 1,758 stocks rose, and 127 remained unchanged [5] - There were 77 stocks hitting the daily limit up and 10 stocks hitting the daily limit down [5]

Core Insights - The cell immunotherapy sector experienced a notable increase of 3.58%, ranking second among concept sectors, with 54 stocks rising, including Shutaishen which hit a 20% limit up [1] - Major inflows of capital were observed in the cell immunotherapy sector, with a net inflow of 831 million yuan, led by Shutaishen with a net inflow of 464 million yuan [1][2] Sector Performance - The top-performing sectors included: - Recombinant proteins: +3.72% - Cell immunotherapy: +3.58% - Sora concept (Wensheng video): +3.51% - AI corpus: +3.42% - Innovative drugs: +3.35% [1] Stock Performance - Key stocks in the cell immunotherapy sector with significant price increases: - Shutaishen: +19.99% - Rongchang Bio: +11.80% - Anke Bio: +6.75% - Zhaoyan New Drug: +4.58% [2][3] - Stocks with notable declines included: - ST Bailing: -3.04% - C Bait: -1.92% - Pruis: -1.37% [1][5] Capital Inflow Ratios - Leading stocks by net capital inflow ratios: - Shutaishen: 19.13% - Dongcheng Pharmaceutical: 11.95% - Rongchang Bio: 10.47% [2][3] Summary of Capital Flows - The cell immunotherapy sector saw significant capital flow, with 30 stocks receiving net inflows, and 8 stocks exceeding 30 million yuan in net inflows [1][2]

Group 1 - The shared bicycle concept sector rose by 1.58%, ranking 9th among concept sectors, with 8 stocks increasing in value [1] - Leading stocks in the shared bicycle sector included Keli Yuan, Shanghai Phoenix, and Hemei Group, which rose by 6.31%, 5.73%, and 4.27% respectively [1] - The stocks that experienced the largest declines were Yong'anxing, Zhongbei Communication, and Xinlong Health, which fell by 2.26%, 0.63%, and 0.43% respectively [1] Group 2 - The shared bicycle concept sector saw a net inflow of 110 million yuan from main funds, with 6 stocks receiving net inflows [2] - Keli Yuan led the net inflow with 75.66 million yuan, followed by Shanghai Phoenix, Boshi Jie, and Hemei Group with net inflows of 49.23 million yuan, 4.38 million yuan, and 2.00 million yuan respectively [2] - The net inflow ratios for Keli Yuan, Shanghai Phoenix, and Boshi Jie were 13.27%, 11.18%, and 5.06% respectively [3] Group 3 - The trading volume and turnover rates for the leading stocks in the shared bicycle sector were as follows: Keli Yuan at 6.31% with a turnover rate of 5.46%, Shanghai Phoenix at 5.73% with a turnover rate of 9.39%, and Hemei Group at 4.27% with a turnover rate of 3.09% [3] - Stocks such as Yong'anxing and Xinlong Health experienced significant declines in net inflow, with Yong'anxing at -131.50 million yuan and a net inflow ratio of -17.73% [4]